The role of intranasal oxytocin in anxiety and depressive disorders: A systematic review of randomized controlled trials

Clinical Psychopharmacology and Neuroscience

Volumn 17, Issue 1, 2019, Pages 1-11

  De Cagna, Francesca ^a   Fusar Poli, Laura ^a,b   Damiani, Stefano ^a   Rocchetti, Matteo ^a   Giovanna, Gianluca ^a   Mori, Alessia ^a   Politi, Pierluigi ^a   Brondino, Natascia ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

Anxiety; Depression; Functional magnetic resonance imaging; Oxytocin; Social behavior

Indexed keywords

OXYTOCIN;

AMYGDALA; ANTIDEPRESSANT ACTIVITY; ANXIETY DISORDER; CINGULATE GYRUS; DEPRESSION; DROWSINESS; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; INSULA; LABORATORY TEST; MAJOR DEPRESSION; MOOD; POSTNATAL DEPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTLESSNESS; REVIEW; SOCIAL COGNITION; SOCIAL PHOBIA; SPIDER PHOBIA; SYSTEMATIC REVIEW; TRANQUILIZING ACTIVITY; VITAL SIGN; XEROSTOMIA;

EID: 85060798116     PISSN: 17381088     EISSN: 20934327     Source Type: Journal    
DOI: 10.9758/cpn.2019.17.1.1     Document Type: Review

References (71)

1. Feldman R, Weller A, Zagoory-Sharon O, Levine A. Evidence for a neuroendocrinological foundation of human affiliation: plasma oxytocin levels across pregnancy and the postpartum period predict mother-infant bonding. Psychol Sci 2007;18: 965-970.
2. Levine A, Zagoory-Sharon O, Feldman R, Weller A. Oxytocin during pregnancy and early postpartum: individual patterns and maternal-fetal attachment. Peptides 2007;28:1162-1169.
3. Rocchetti M, Radua J, Paloyelis Y, Xenaki LA, Frascarelli M, Caverzasi E, et al. Neurofunctional maps of the 'maternal brain' and the effects of oxytocin: a multimodal voxel-based meta-analysis. Psychiatry Clin Neurosci 2014;68:733-751.
4. Feeser M, Fan Y, Weigand A, Hahn A, Gärtner M, Böker H, et al. Oxytocin improves mentalizing-pronounced effects for individuals with attenuated ability to empathize. Psychoneuroendocrinology 2015;53:223-232.
5. Radke S, de Bruijn ERA. Does oxytocin affect mind-reading? A replication study. Psychoneuroendocrinology 2015;60:75-81.
6. Bartz JA, Zaki J, Bolger N, Hollander E, Ludwig NN, Kolevzon A, et al. Oxytocin selectively improves empathic accuracy. Psychol Sci 2010;21:1426-1428.
7. Brondino N, Fusar-Poli L, Politi P. Something to talk about: gossip increases oxytocin levels in a near real-life situation. Psychoneuroendocrinology 2017;77:218-224.
8. Guastella AJ, Einfeld SL, Gray KM, Rinehart NJ, Tonge BJ, Lambert TJ, et al. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatry 2010;67:692-694.
9. Lischke A, Berger C, Prehn K, Heinrichs M, Herpertz SC, Domes G. Intranasal oxytocin enhances emotion recognition from dynamic facial expressions and leaves eye-gaze unaffected. Psychoneuroendocrinology 2012;37:475-481.
10. Domes G, Heinrichs M, Michel A, Berger C, Herpertz SC. Oxytocin improves "mind-reading" in humans. Biol Psychiatry 2007;61:731-733.
11. Pedersen CA, Gibson CM, Rau SW, Salimi K, Smedley KL, Casey RL, et al. Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia. Schizophr Res 2011;132:50-53.
12. Williams DR, Bürkner PC. Effects of intranasal oxytocin on symptoms of schizophrenia: A multivariate Bayesian meta-analysis. Psychoneuroendocrinology 2017;75:141-151.
13. Rutigliano G, Rocchetti M, Paloyelis Y, Gilleen J, Sardella A, Cappucciati M, et al. Peripheral oxytocin and vasopressin: Biomarkers of psychiatric disorders? A comprehensive systematic review and preliminary meta-analysis. Psychiatry Res 2016;241:207-220.
14. Stoop R. Neuromodulation by oxytocin and vasopressin. Neuron 2012;76:142-159.
15. Hashimoto H, Uezono Y, Ueta Y. Pathophysiological function of oxytocin secreted by neuropeptides: a mini review. Pathophysiology 2012;19:283-298.
16. Neumann ID, Landgraf R. Balance of brain oxytocin and vasopressin: implications for anxiety, depression, and social behaviors. Trends Neurosci 2012;35:649-659.
17. Slattery DA, Neumann ID. No stress please! Mechanisms of stress hyporesponsiveness of the maternal brain. J Physiol 2008;586:377-385.
18. Waldherr M, Neumann ID. Centrally released oxytocin mediates mating-induced anxiolysis in male rats. Proc Natl Acad Sci U S A 2007;104:16681-16684.
19. Nyuyki KD, Waldherr M, Baeuml S, Neumann ID. Yes, I am ready now: differential effects of paced versus unpaced mating on anxiety and central oxytocin release in female rats. PLoS One 2011;6:e23599.
20. Neumann ID, Slattery DA. Oxytocin in general anxiety and social fear: a translational approach. Biol psychiatry 2016;79: 213-221.
21. Matsuzaki M, Matsushita H, Tomizawa K, Matsui H. Oxytocin: a therapeutic target for mental disorders. J Physiol Sci 2012;62:441-444.
22. McQuaid RJ, McInnis OA, Abizaid A, Anisman H. Making room for oxytocin in understanding depression. Neurosci Biobehav Rev 2014;45:305-322.
23. Di Simplicio M, Massey-Chase R, Cowen PJ, Harmer CJ. Oxytocin enhances processing of positive versus negative emotional information in healthy male volunteers. J Psychopharmacol 2009;23:241-248.
24. Baskerville TA, Douglas AJ. Dopamine and oxytocin interactions underlying behaviors: potential contributions to behavioral disorders. CNS Neurosci Ther 2010;16:e92-e123.
25. Kroll-Desrosiers AR, Nephew BC, Babb JA, Guilarte-Walker Y, Moore Simas TA, Deligiannidis KM. Association of peripartum synthetic oxytocin administration and depressive and anxiety disorders within the first postpartum year. Depress Anxiety 2017;34:137-146.
26. Bell AF, Carter CS, Steer CD, Golding J, Davis JM, Steffen AD, et al. Interaction between oxytocin receptor DNA methylation and genotype is associated with risk of postpartum depression in women without depression in pregnancy. Fron Genet 2015;6:243.
27. Stuebe AM, Grewen K, Meltzer-Brody S. Association between maternal mood and oxytocin response to breastfeeding. J Womens Health (Larchmt) 2013;22:352-361.
28. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med 2009;3: e123-e130.
29. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, D.C.:APA Press;2013.
30. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
31. Fang A, Hoge EA, Heinrichs M, Hofmann SG. Attachment style moderates the effects of oxytocin on social behaviors and cognitions during social rejection: applying an RDoC framework to social anxiety. Clin Psychol Sci 2014;2:740-747.
32. Fang A, Treadway MT, Hofmann SG. Working hard for oneself or others: Effects of oxytocin on reward motivation in social anxiety disorder. Biol Psychol 2017;127:157-162.
33. Guastella AJ, Howard AL, Dadds MR, Mitchell P, Carson DS. A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder. Psychoneuroendocrinology 2009;34:917-923.
34. Dodhia S, Hosanagar A, Fitzgerald DA, Labuschagne I, Wood AG, Nathan PJ, et al. Modulation of resting-state amygdala-frontal functional connectivity by oxytocin in generalized social anxiety disorder. Neuropsychopharmacology 2014;39: 2061-2069.
35. Gorka SM, Fitzgerald DA, Labuschagne I, Hosanagar A, Wood AG, Nathan PJ, et al. Oxytocin modulation of amygdala functional connectivity to fearful faces in generalized social anxiety disorder. Neuropsychopharmacology 2015;40:278-286.
36. Labuschagne I, Phan KL, Wood A, Angstadt M, Chua P, Heinrichs M, et al. Oxytocin attenuates amygdala reactivity to fear in generalized social anxiety disorder. Neuropsychopharmacology 2010;35:2403-2413.
37. Labuschagne I, Phan KL, Wood A, Angstadt M, Chua P, Heinrichs M, et al. Medial frontal hyperactivity to sad faces in generalized social anxiety disorder and modulation by oxytocin. Int J Neuropsychopharmacol 2012;15:883-896.
38. Acheson DT, Feifel D, Kamenski M, McKinney R, Risbrough VB. Intranasal oxytocin administration prior to exposure therapy for arachnophobia impedes treatment response. Depress Anxiety 2015;32:400-407.
39. Klorman R, Weerts TC, Hastings JE, Melamed BG, Lang PJ. Psychometric description of some specific-fear questionnaires. Behav Ther 1974;5:401-409.
40. Szymanski J, O'Donohue W. Fear of Spiders Questionnaire. J Behav Ther Exp Psychiatry 1995;26:31-34.
41. Guy W; US National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs. ECDEU assessment manual for psychopharmacology. Rockvile, MD:US Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration:1976.
42. Turner SM, Beidel DC, Dancu CV. SPAI Manual. Toronto: Multi-Health Systems;1996.
43. Liebowitz MR. Social phobia. Mod Probl Pharmacopsychiatry 1987;22:141-173.
44. Mark RL. A brief version of the fear of negative evaluation scale. Personal Soc Psychol Bull 1983;9:371-375.
45. Rapee RM, Abbott MJ. Mental representation of observable attributes in people with social phobia. J Behav Ther Exp Psychiatry 2006;37:113-126.
46. Spielberg CD, Gorsuch RL, Lushene RE. STAI manual for the State-Trait Anxiety Inventory. Palo Alto, CA:Consulting Psychologists Press;1970.
47. Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol 1988;54:1063-1070.
48. Bond A, Lader M. The use of analogue scales in rating subjective feelings. Br J Med Psychol 1974;47:211-218.
49. McNair DM, Lorr M, Droppleman LF. Manual for the profile of mood states. San Diego:Educational and Industrial Testing Service;1971.
50. Williams KD, Cheung CK, Choi W. Cyberostracism: effects of being ignored over the Internet. J Pers Soc Psychol 2000;79: 748-762.
51. Williams KD, Jarvis B. Cyberball: a program for use in research on interpersonal ostracism and acceptance. Behav Res Methods 2006;38:174-180.
52. Posner MI. Orienting of attention. Q J Exp Psychol 1980; 32:3-25.
53. Posner MI, Snyder CR, Davidson BJ. Attention and the detection of signals. J Exp Psychol 1980;109:160-174.
54. Treadway MT, Buckholtz JW, Schwartzman AN, Lambert WE, Zald DH. Worth the ‘EEfRT’? The effort expenditure for rewards task as an objective measure of motivation and anhedonia. PLoS ONE 2009;4:e6598.
55. Rapee RM, Lim L. Discrepancy between self- and observer ratings of performance in social phobics. J Abnorm Psychol 1992;101:728-731.
56. Mochcovitch MD, da Rocha Freire RC, Garcia RF, Nardi AE. A systematic review of fMRI studies in generalized anxiety disorder: Evaluating its neural and cognitive basis. J Affect Disord 2014;167:336-342.
57. Stein MB, Simmons AN, Feinstein JS, Paulus MP. Increased amygdala and insula activation during emotion processing in anxiety-prone subjects. Am J Psychiatry 2007;164:318-327.
58. Shin LM, Liberzon I. The neurocircuitry of fear, stress, and anxiety disorders. Neuropsychopharmacology 2010;35:169-191.
59. Sripada CS, Phan KL, Labuschagne I, Welsh R, Nathan PJ, Wood AG. Oxytocin enhances resting-state connectivity between amygdala and medial frontal cortex. Int J Neuropsychopharmacol 2013;16:255-260.
60. Clarici A, Pellizzoni S, Guaschino S, Alberico S, Bembich S, Giuliani R, et al. Intranasal adminsitration of oxytocin in postnatal depression: implications for psychodynamic psychotherapy from a randomized double-blind pilot study. Front Psychol 2015;6:426.
61. Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression. Development of the 10-item Edinburgh postnatal depression scale. Br J Psychiatry 1987;150:782-786.
62. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-296.
63. Mah BL, Van Ijzendoorn MH, Smith R, Bakermans-Kranenburg MJ. Oxytocin in postnatally depressed mothers: its influence on mood and expressed emotion. Prog Neuropsychopharmacol Biol Psychiatry 2013;40:267-272.
64. MacDonald K, MacDonald TM, Brüne M, Lamb K, Wilson MP, Golshan S, et al. Oxytocin and psychotherapy: a pilot study of its physiological, behavioral and subjective effects in males with depression. Psychoneuroendocrinology. 2013;38: 2831-2843.
65. Pincus D, Kose S, Arana A, Johnson K, Morgan PS, Borckardt J, et al. Inverse effects of oxytocin on attributing mental activity to others in depressed and healthy subjects: a double-blind placebo controlled FMRI study. Front Psychiatry 2010;1:134.
66. Domes G, Normann C, Heinrichs M. The effect of oxytocin on attention to angry and happy faces in chronic depression. BMC Psychiatry 2016;16:92.
67. Mah BL, Bakermans-Kranenburg MJ, Van IMH, Smith R. Oxytocin promotes protective behavior in depressed mothers: a pilot study with the enthusiastic stranger paradigm. Depress Anxiety 2015;32:76-81.
68. Mah BL, Van Ijzendoorn MH, Out D, Smith R, Bakermans-Kranenburg MJ. The effects of intranasal oxytocin administration on sensitive caregiving in mothers with postnatal depression. Child Psychiatry Hum Dev 2017;48:308-315.
69. MacDonald E, Dadds MR, Brennan JL, Williams K, Levy F, Cauchi AJ. A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research. Psychoneuroendocrinology 2011;36:1114-1126.
70. Serretti A. The present and future of precision medicine in psychiatry: focus on clinical psychopharmacology of antidepressants. Clin Psychopharmacol Neurosci 2018;16:1-6.
71. Churchland PS, Winkielman P. Modulating social behavior with oxytocin: how does it work? What does it mean? Horm Behav 2012;61:392-399.